IL256912B2 - Methods of treating developmental disorders with gaboxadol - Google Patents

Methods of treating developmental disorders with gaboxadol

Info

Publication number
IL256912B2
IL256912B2 IL256912A IL25691218A IL256912B2 IL 256912 B2 IL256912 B2 IL 256912B2 IL 256912 A IL256912 A IL 256912A IL 25691218 A IL25691218 A IL 25691218A IL 256912 B2 IL256912 B2 IL 256912B2
Authority
IL
Israel
Prior art keywords
gaboxadol
patient
pharmaceutical composition
pharmaceutically acceptable
hours
Prior art date
Application number
IL256912A
Other languages
English (en)
Hebrew (he)
Other versions
IL256912A (en
IL256912B1 (en
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of IL256912A publication Critical patent/IL256912A/en
Publication of IL256912B1 publication Critical patent/IL256912B1/en
Publication of IL256912B2 publication Critical patent/IL256912B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL256912A 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol IL256912B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US201662346763P 2016-06-07 2016-06-07
US15/209,862 US20170014393A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol
PCT/US2016/042238 WO2017015049A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol

Publications (3)

Publication Number Publication Date
IL256912A IL256912A (en) 2018-03-29
IL256912B1 IL256912B1 (en) 2023-09-01
IL256912B2 true IL256912B2 (en) 2024-01-01

Family

ID=57774846

Family Applications (2)

Application Number Title Priority Date Filing Date
IL256912A IL256912B2 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol
IL305342A IL305342A (en) 2015-07-17 2016-07-14 Methods for treating developmental disorders with gaboxadol

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL305342A IL305342A (en) 2015-07-17 2016-07-14 Methods for treating developmental disorders with gaboxadol

Country Status (17)

Country Link
US (8) US20170014393A1 (enExample)
EP (2) EP3324961B1 (enExample)
JP (3) JP2018520189A (enExample)
KR (2) KR20180031721A (enExample)
CN (2) CN116531370A (enExample)
AU (2) AU2016295138B2 (enExample)
BR (1) BR112018000933A2 (enExample)
CA (1) CA2992734A1 (enExample)
CL (1) CL2018000142A1 (enExample)
CO (1) CO2018000375A2 (enExample)
ES (1) ES3021189T3 (enExample)
HK (1) HK1250951A1 (enExample)
IL (2) IL256912B2 (enExample)
MX (2) MX391708B (enExample)
PE (2) PE20230735A1 (enExample)
TW (2) TWI819995B (enExample)
WO (1) WO2017015049A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3372229T1 (sl) 2014-06-06 2021-09-30 Ovid Therapeutics, Inc. Postopki za povečanje tonične inhibicije in zdravljenje angelman sindroma
BR112018000933A2 (pt) 2015-07-17 2018-09-04 Ovid Therapeutics Inc métodos de tratamento de um distúrbio de desenvolvimento
JP2019524816A (ja) 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
AU2017363598A1 (en) * 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
MX2020001342A (es) 2017-08-04 2020-08-31 Ovid Therapeutics Inc Uso de gaboxadol en el tratamiento contra diabetes y afecciones relacionadas.
MX2020004974A (es) * 2017-11-14 2020-08-24 Sk Biopharmaceuticals Co Ltd Uso del compuesto de carbamato para reducir o tratar trastornos del desarrollo que incluyen sindrome x fragil, sindrome de angelman o sindrome de rett.
CN112739353A (zh) * 2018-06-14 2021-04-30 奥维德医疗公司 Mir-92a或mir-145在治疗安格曼综合征中的用途
EP3823619A4 (en) * 2018-08-22 2021-11-17 Ovid Therapeutics Inc. USE OF GABOXADOL FOR TREATMENT OF GIOMETAL TRACT DISORDERS AND ASTHMA
MX2021003302A (es) 2018-09-20 2021-05-13 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del sindrome de tourette, los tics y la tartamudez.
WO2020106927A1 (en) 2018-11-21 2020-05-28 Certego Therapeutics Gaboxadol for reducing risk of suicide and rapid relief of depression
WO2020106976A1 (en) * 2018-11-21 2020-05-28 Certego Therapeutics Combination of gaboxadol and lithium for the treatment of psychiatric disorders
MX2021007224A (es) 2018-12-17 2021-09-23 Ovid Therapeutics Inc Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas.
CN114340597B (zh) * 2019-06-07 2025-01-28 帕克斯医学有限公司 用于治疗中枢神经系统障碍的组合物和方法
AU2020313930A1 (en) * 2019-07-15 2022-02-03 Ovid Therapeutics Inc. Pharmaceutical formulations containing gaboxadol for therapeutic treatment
JP2023507764A (ja) * 2019-12-18 2023-02-27 オービッド・セラピューティクス・インコーポレイテッド １ｐ３６欠失症候群の治療的処置のためのガボキサドール
IL298334A (en) 2020-05-20 2023-01-01 Certego Therapeutics Inc Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
WO2006013397A1 (en) * 2004-08-06 2006-02-09 Merck Sharp & Dohme Limited Combination of gaboxadol and 5ht2a antagonists
US20080269278A1 (en) * 2004-04-02 2008-10-30 H. Lundbeck A/S Treatment of Impaired Respiratory Function with Gaboxadol
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
DK270278A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Cycliske aminosyrer
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
AU2002227052A1 (en) * 2000-11-30 2002-06-11 University Of Florida Treatments for neurogenetic disorders, impulse control disorders, and wound healing
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
IL158733A0 (en) 2001-05-21 2004-05-12 Lundbeck & Co As H Granular preparations of gaboxadol
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
MXPA05013016A (es) 2003-06-25 2006-03-02 Lundbeck & Co As H Gaboxadol para el tratamiento de la depresion y otros trastornos afectivos.
EP1663218A1 (en) 2003-09-10 2006-06-07 MERCK SHARP & DOHME LTD. Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050215521A1 (en) 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
GB0402118D0 (en) 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
ZA200607427B (en) * 2004-04-02 2009-02-25 Lundbeck & Co As H Treatment of impaired respiratory function with gaboxadol
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
EP1942879A1 (en) * 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
RS55585B1 (sr) * 2006-11-22 2017-06-30 Clinical Research Associates LLC Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
CN102137667A (zh) * 2008-09-01 2011-07-27 H.隆德贝克有限公司 包含加波沙朵和patl或oat抑制剂的药物组合物
US20100286762A1 (en) 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
DK2621282T3 (da) 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US9480695B2 (en) 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
WO2013056159A1 (en) 2011-10-13 2013-04-18 Jaleva Pharmaceuticals, Llc Methods and compositions for rapid transbuccal delivery of active agents
DK2925327T3 (da) * 2012-11-30 2024-03-25 Univ California Allopregnanolon til behandling, reduktion eller lindring af symptomer på fødselsdepression
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
SI3372229T1 (sl) * 2014-06-06 2021-09-30 Ovid Therapeutics, Inc. Postopki za povečanje tonične inhibicije in zdravljenje angelman sindroma
US9802945B2 (en) 2014-06-12 2017-10-31 Pfizer Limited Imidazopyridazine derivatives as modulators of the GABAA receptor activity
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
BR112018000933A2 (pt) * 2015-07-17 2018-09-04 Ovid Therapeutics Inc métodos de tratamento de um distúrbio de desenvolvimento
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
PE20181332A1 (es) 2015-08-11 2018-08-20 Ovid Therapeutics Inc Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
WO2017070680A1 (en) 2015-10-22 2017-04-27 Cavion Llc Methods for treating angelman syndrome and related disorders
JP2019517469A (ja) 2016-05-26 2019-06-24 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ピプラドロールを用いる行動症候群の治療方法
JP2019524816A (ja) 2016-08-11 2019-09-05 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． てんかん性障害の処置のための方法および組成物
AU2017363598A1 (en) 2016-11-22 2019-05-23 Ovid Therapeutics Inc. Methods of treating developmental disorders and/or seizure disorders with flupirtine
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20080269278A1 (en) * 2004-04-02 2008-10-30 H. Lundbeck A/S Treatment of Impaired Respiratory Function with Gaboxadol
WO2006013397A1 (en) * 2004-08-06 2006-02-09 Merck Sharp & Dohme Limited Combination of gaboxadol and 5ht2a antagonists
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EIXOTO M F ET AL,, EFFECTS OF GABAERGIC DRUGS ON RESERPINE-INDUCED ORAL DYSKINESIA, 7 May 2005 (2005-05-07) *
GUNVANT K. THAKER,, BRAIN [GAMMA]-AMINOBUTYRIC ACID ABNORMALITY IN TARDIVE DYSKINESIA : REDUCTION IN CEREBROSPINAL FLUID GABA LEVELS AND THERAPEUTIC RESPONSE TO GABA AGONIST TREATMENT, 1 June 1987 (1987-06-01) *
K. EGAWA ET AL, DECREASED TONIC INHIBITION IN CEREBELLAR GRANULE CELLS CAUSES MOTOR DYSFUNCTION IN A MOUSE MODEL OF ANGELMAN SYNDROME, 5 December 2012 (2012-12-05) *
LOZANO REYMUNDO ET AL,, MODULATION OF THE GABAERGIC PATHWAY FOR THE TREATMENT OF FRAGILE X SYNDROME, 1 January 2014 (2014-01-01) *
OLMOS-SERRANO J. L. ET AL.,, THE GABA(A) RECEPTOR AGONIST THIP AMELIORATES SPECIFIC BEHAVIORAL DEFICITS IN THE MOUSE MODEL OF FRAGILE X SYNDROME, 31 December 2011 (2011-12-31) *

Also Published As

Publication number Publication date
US12465597B2 (en) 2025-11-11
US20190255027A1 (en) 2019-08-22
EP4541420A3 (en) 2025-06-25
JP2018520189A (ja) 2018-07-26
KR20180031721A (ko) 2018-03-28
JP2023103375A (ja) 2023-07-26
IL305342A (en) 2023-10-01
HK1250951A1 (zh) 2019-01-18
TW201707700A (zh) 2017-03-01
ES3021189T3 (en) 2025-05-26
US20180098974A1 (en) 2018-04-12
AU2016295138B2 (en) 2021-11-04
AU2021250862A1 (en) 2021-11-04
MX391708B (es) 2025-03-21
AU2016295138A1 (en) 2018-02-08
PE20190338A1 (es) 2019-03-07
US20210030727A1 (en) 2021-02-04
US20230071127A1 (en) 2023-03-09
EP3324961A4 (en) 2019-03-13
US20180338960A1 (en) 2018-11-29
AU2021250862B2 (en) 2023-11-09
CN108024997A (zh) 2018-05-11
EP3324961A1 (en) 2018-05-30
EP3324961C0 (en) 2025-03-19
TW202325293A (zh) 2023-07-01
CA2992734A1 (en) 2017-01-26
CN116531370A (zh) 2023-08-04
WO2017015049A1 (en) 2017-01-26
EP4541420A2 (en) 2025-04-23
JP2021130687A (ja) 2021-09-09
CL2018000142A1 (es) 2018-07-13
BR112018000933A2 (pt) 2018-09-04
IL256912A (en) 2018-03-29
MX2022004734A (es) 2022-05-13
KR20240160666A (ko) 2024-11-11
TWI819995B (zh) 2023-11-01
PE20230735A1 (es) 2023-05-03
US20190321342A1 (en) 2019-10-24
MX2018000745A (es) 2018-08-15
US20190117632A1 (en) 2019-04-25
CO2018000375A2 (es) 2018-04-19
IL256912B1 (en) 2023-09-01
US11096929B2 (en) 2021-08-24
EP3324961B1 (en) 2025-03-19
US20170014393A1 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
IL256912B2 (en) Methods of treating developmental disorders with gaboxadol
AU2021257943A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine and/or gaboxadol
US10426746B2 (en) Methods of treating developmental disorders with biguanides
Tuite et al. Recent developments in the pharmacological treatment of Parkinson’s disease
US20180344709A1 (en) Use of gaboxadol in the treatment of tinnitus
US11090293B2 (en) Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
HK40012437A (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine